First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics - Test2 - elhamkhani - TriplyDB

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics

http://www.wikidata.org/entity/Q28383451

about

Mitochondrial disorders in children: toward development of small-molecule treatment strategies Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy Microglial cell dysregulation in brain aging and neurodegeneration Mitochondrial oxidative stress in aging and healthspan Quality control systems in cardiac aging Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis Serendipity and the discovery of novel compounds that restore mitochondrial plasticity Mitochondrial dysfunction in cardiac aging Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-Lymphocytes Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects.Diabetic cardiomyopathy: where we are and where we are going.Cardiolipin content, linoleic acid composition, and tafazzin expression in response to skeletal muscle overload and unload stimuli.Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue.Long-term survival in a child with severe encephalopathy, multiple respiratory chain deficiency and GFM1 mutations.Potential compounds for the treatment of mitochondrial disease.SS-31 attenuates TNF-α induced cytokine release from C2C12 myotubes.Reconsidering the Role of Mitochondria in Aging.Contribution of mitochondrial oxidative stress to hypertension.Compartment-specific Control of Reactive Oxygen Species Scavenging by Antioxidant Pathway Enzymes.Restoration of Mitochondrial Cardiolipin Attenuates Cardiac Damage in Swine Renovascular Hypertension Bendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border zone of the infarcted heart.Protective effect of mitochondria‑targeted peptide MTP‑131 against oxidative stress‑induced apoptosis in RGC‑5 cells.Mitochondrial injury and dysfunction in hypertension-induced cardiac damage.Mitochondria: a pathogenic paradigm in hypertensive renal disease.Cardiolipin-cytochrome c complex: Switching cytochrome c from an electron-transfer shuttle to a myoglobin- and a peroxidase-like heme-protein.The Aging Heart Mutations causing mitochondrial disease: What is new and what challenges remain?Pro- and Antioxidant Functions of the Peroxisome-Mitochondria Connection and Its Impact on Aging and Disease Mitochondrial Therapies in Heart Failure.The Emerging Role of Mitochondrial Targeting in Kidney Disease.Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure.Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series.A mitochondrial therapeutic reverses visual decline in mouse models of diabetes Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia.Metabolic cardiomyopathies - fighting the next epidemic.Mitochondrial-targeted catalase is good for the old mouse proteome, but not for the young: 'reverse' antagonistic pleiotropy?Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet.Mitochondrial pharmacology: energy, injury and beyond.

P2860

Q26767327-B9A83A89-68CD-4275-BFA2-0C3C8136F5D3 Q26775037-DD84C543-9B1F-4031-85E8-82127AE8BE94 Q26800212-B9BF6696-8B91-46DF-99A3-C08D03C3EECB Q27025099-1A0E417D-C9B8-42CA-8D37-10056E846D6A Q28084341-CFAE2E04-08DD-44AF-8FE3-DE0DB8AE3FBA Q28085102-D2E73C72-CF76-4D8F-9EAC-5C5600DCCBF0 Q28383442-4C4A33ED-161E-4A61-B2CB-98240C2F1A1F Q28384256-1D7EDE91-D312-4C7D-AA3A-18E1907961AC Q28389063-02014A99-0309-40D9-8EF5-735BCE25CCD4 Q28396128-E794CAFB-12F7-4F36-84BD-A6CC779758F9 Q28552702-2FDBA7BF-B158-46FE-91E5-5FF394238794 Q33565870-EE7C60D7-30F8-46D9-809F-05D28761B7B1 Q33690717-0E0D7E2B-6B6C-472F-8ADB-012B1910AF7E Q33700649-BF7F8E4A-E1CE-47B4-8BD2-3A835268C997 Q33813591-CF4B5EB5-1149-4766-B2C4-AEDC825A7A3B Q35206060-26516529-2149-4E1F-BA4B-2D5BACC85155 Q35847813-043C2EB1-32EC-4E83-BA6D-D4C4AA9BD6B3 Q36017207-D3FF1B83-A583-4885-BC9D-FD57855C227E Q36181511-CE13D551-F3D8-4290-88E3-3E7F53F12BC8 Q36617393-61FAF33A-3EE4-4470-80DC-500116302053 Q36987663-0CC23726-641D-4798-86CD-CE962C3FF033 Q37076104-C359C4FA-D28D-494E-94A7-A1EF8B4C4FD1 Q37151412-A7F84923-1693-4E34-836B-352288B627D4 Q37720064-BD200771-65AB-4DB7-B541-1AAA655B37D6 Q38266758-A1CEAD02-7ADF-4E14-8CF8-DAEFF740F337 Q38268844-CAC29B4B-4111-4A81-BCBC-5E37609B6F96 Q38413016-B468C8BD-0FD8-48A2-B318-C6C5C3579DBA Q38578328-BC271348-7E31-4569-9D12-3C8616BF98D5 Q38592664-00178F2D-6E63-405C-B9E5-878EEF5D7857 Q38641954-58080267-8633-4FA0-9391-67BCBE2CEC36 Q38759545-31BF1194-BE55-424E-8637-F8EF8706494D Q39252634-751DAF5D-5F4B-49F9-B3BA-5AE2352B87A5 Q39401767-CC6CC723-6546-43A5-8436-59C6A069EC4B Q39418950-0A8EDEAA-D9C6-4C92-AB9D-2E9C9C64B04C Q40878074-B0AD3EF7-091B-4A63-BB6A-71C65C17F438 Q41548664-E7BF65BE-3CF4-4422-B5DC-3A78D0B99571 Q42050369-210832DB-66DC-40DD-916A-31D40A72DF3B Q42154295-1EFA825E-A759-4038-8272-C47CE5009A36 Q42367553-A44B18D0-C745-40C2-A3A8-929960493589 Q42374835-48B7045C-D314-44F9-A6AA-04DFE7B01BDC

P2860

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics

http://www.wikidata.org/entity/Q28383451

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@ast

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@en

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@nl

type

label

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@ast

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@en

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@nl

prefLabel

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@ast

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@en

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@nl

P1433

Q28383451-6A361324-BA0D-4A7A-8E92-CA9D5D633694

P1476

Q28383451-F59104EE-C3B5-41E8-89BA-4221C3009E4B

P2093

Q28383451-8EA06182-A94B-4371-B7E2-BBBAEF631A9B

P2860

Q28383451-0370091C-84A0-4369-BA3E-0B74875D7682

Q28383451-04D758A6-DE43-429F-8CE8-4C01DFCA7273

Q28383451-05AFBB6F-E0A3-474F-ACDC-7CCAFAFAA6AE

Q28383451-072DC736-CCD8-439F-92F3-F2585A57371C

Q28383451-0AE3E9BC-4CC0-4CED-9691-5702692B028C

Q28383451-0BC5109A-BB54-4E41-8A36-B12BB4AF4B14

Q28383451-0CA24377-32C3-4DEB-AF72-C68534476996

Q28383451-0CEF634D-2EA1-4D6B-84B9-07C379060585

Q28383451-0E68E5F9-45D4-4115-B9FC-552FE85FA62E

Q28383451-0E69638A-89A8-4BB7-870E-0875DC571A43

P304

Q28383451-EE114BA2-3EF7-435A-B062-D6C767CCF8D8

P31

Q28383451-615A5634-3166-4A77-A47C-ED5134020F1D

P3181

Q28383451-8A847BF8-89DE-4333-B3A3-D0BED3BF89A0

P356

Q28383451-BE115F90-6429-4133-A437-11F4D2C72760

P407

Q28383451-2BF2A93D-DAFA-4D23-94E3-608BFC5148C1

P433

Q28383451-E90D5F4D-0737-45DB-B575-9ECE6D4D4CA9

P478

Q28383451-699A3615-25E2-437A-85EE-7D0267FEBFFC

P577

Q28383451-5F6E78F1-E38F-443C-A908-F6867EBAB8FB

P5875

Q28383451-E268E017-E6BA-4593-B1B6-87A82892996F

P698

Q28383451-E28D6770-9E73-4D23-ACE5-397C47616725

P921

Q28383451-C0572B56-501D-4CAE-A3F4-990B95501185

P932

Q28383451-0DC2DB7D-83E9-4094-97AD-B220D80A009F

P3181

P356

P1433

British Journal of Pharmacology

P1476

First-in-class cardiolipin-pro ...... re mitochondrial bioenergetics

@en

P2093

Hazel H Szeto

http://www.w3.org/2001/XMLSchema#string

P2860

Selective early cardiolipin peroxidation after traumatic brain injury: an oxidative lipidomics analysis

Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of brain injury

Cardiolipin switch in mitochondria: shutting off the reduction of cytochrome C and turning on the peroxidase activity

Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors

LC/MS characterization of rotenone induced cardiolipin oxidation in human lymphocytes: implications for mitochondrial dysfunction associated with Parkinson's disease

Mitochondria targeting of non-peroxidizable triphenylphosphonium conjugated oleic acid protects mouse embryonic cells against apoptosis: role of cardiolipin remodeling

Comparison of lymphoblast mitochondria from normal subjects and patients with Barth syndrome using electron microscopic tomography

Making heads or tails of phospholipids in mitochondria

Cardiolipin membrane domains in prokaryotes and eukaryotes

Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer

P304

2029-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1195183

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/BPH.12461

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

171

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261569229

http://www.w3.org/2001/XMLSchema#string

P698

24117165

http://www.w3.org/2001/XMLSchema#string

P921

P932

3976620

http://www.w3.org/2001/XMLSchema#string